These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1324 related articles for article (PubMed ID: 30877491)

  • 1. Recent Updates on the Use of PCSK9 Inhibitors in Patients with Atherosclerotic Cardiovascular Disease.
    Dixon DL; Pamulapati LG; Bucheit JD; Sisson EM; Smith SR; Kim CJ; Wohlford GF; Pozen J
    Curr Atheroscler Rep; 2019 Mar; 21(5):16. PubMed ID: 30877491
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.
    Schmidt AF; Carter JL; Pearce LS; Wilkins JT; Overington JP; Hingorani AD; Casas JP
    Cochrane Database Syst Rev; 2020 Oct; 10(10):CD011748. PubMed ID: 33078867
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alirocumab therapy in individuals with type 2 diabetes mellitus and atherosclerotic cardiovascular disease: analysis of the ODYSSEY DM-DYSLIPIDEMIA and DM-INSULIN studies.
    Ray KK; Del Prato S; Müller-Wieland D; Cariou B; Colhoun HM; Tinahones FJ; Domenger C; Letierce A; Mandel J; Samuel R; Bujas-Bobanovic M; Leiter LA
    Cardiovasc Diabetol; 2019 Nov; 18(1):149. PubMed ID: 31706300
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk reduction: A systematic review and meta-analysis.
    Imran TF; Khan AA; Has P; Jacobson A; Bogin S; Khalid M; Khan A; Kim S; Erqou S; Choudhary G; Aspry K; Wu WC
    PLoS One; 2023; 18(12):e0295359. PubMed ID: 38055686
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systematic Review and Network Meta-Analysis on the Efficacy of Evolocumab and Other Therapies for the Management of Lipid Levels in Hyperlipidemia.
    Toth PP; Worthy G; Gandra SR; Sattar N; Bray S; Cheng LI; Bridges I; Worth GM; Dent R; Forbes CA; Deshpande S; Ross J; Kleijnen J; Stroes ESG
    J Am Heart Assoc; 2017 Oct; 6(10):. PubMed ID: 28971955
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PCSK9 inhibitors and cardiovascular outcomes.
    Steffens D; Bramlage P; Scheeff C; Kasner M; Hassanein A; Friebel J; Rauch-Kröhnert U
    Expert Opin Biol Ther; 2020 Jan; 20(1):35-47. PubMed ID: 31593483
    [No Abstract]   [Full Text] [Related]  

  • 7. Associations between lower levels of low-density lipoprotein cholesterol and cardiovascular events in very high-risk patients: Pooled analysis of nine ODYSSEY trials of alirocumab versus control.
    Vallejo-Vaz AJ; Ray KK; Ginsberg HN; Davidson MH; Eckel RH; Lee LV; Bessac L; Pordy R; Letierce A; Cannon CP
    Atherosclerosis; 2019 Sep; 288():85-93. PubMed ID: 31349086
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes.
    Roe MT; Li QH; Bhatt DL; Bittner VA; Diaz R; Goodman SG; Harrington RA; Jukema JW; Lopez-Jaramillo P; Lopes RD; Louie MJ; Moriarty PM; Szarek M; Vogel R; White HD; Zeiher AM; Baccara-Dinet MT; Steg PG; Schwartz GG
    Circulation; 2019 Nov; 140(19):1578-1589. PubMed ID: 31475572
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.
    Schmidt AF; Pearce LS; Wilkins JT; Overington JP; Hingorani AD; Casas JP
    Cochrane Database Syst Rev; 2017 Apr; 4(4):CD011748. PubMed ID: 28453187
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-PCSK9 antibodies for hypercholesterolaemia: Overview of clinical data and implications for primary care.
    Descamps OS; Fraass U; Dent R; März W; Gouni-Berthold I
    Int J Clin Pract; 2017 Aug; 71(8):. PubMed ID: 28750477
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PCSK9 Inhibitors in Secondary Prevention-An Opportunity for Personalized Therapy.
    Board C; Kelly MS; Shapiro MD; Dixon DL
    J Cardiovasc Pharmacol; 2020 May; 75(5):410-420. PubMed ID: 32379108
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low-Density Lipoprotein Cholesterol After an Acute Coronary Syndrome: How Low to Go?
    Qamar A; Libby P
    Curr Cardiol Rep; 2019 Jun; 21(8):77. PubMed ID: 31250329
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adoption of PCSK9 Inhibitors Among Patients With Atherosclerotic Disease.
    Dayoub EJ; Eberly LA; Nathan AS; Khatana SAM; Adusumalli S; Navar AM; Giri J; Groeneveld PW
    J Am Heart Assoc; 2021 May; 10(9):e019331. PubMed ID: 33904340
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PCSK9 Inhibitors' New Users: Analysis of Prescription Patterns and Patients' Characteristics from an Italian Real-world Study.
    Piccinni C; Antonazzo IC; Maggioni AP; Pedrini A; Calabria S; Ronconi G; Dondi L; Martini N; Roberto G; Sampietro T; Sbrana F; Pino BD; Bigazzi F; Surdo GL; Volpi E; Biagini S; Gini R
    Clin Drug Investig; 2020 Feb; 40(2):173-181. PubMed ID: 31797311
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacological Strategies beyond Statins: Ezetimibe and PCSK9 Inhibitors.
    Choi JY; Na JO
    J Lipid Atheroscler; 2019 Sep; 8(2):183-191. PubMed ID: 32821708
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment with PCSK9 inhibitors induces a more anti-atherogenic HDL lipid profile in patients at high cardiovascular risk.
    Ingueneau C; Hollstein T; Grenkowitz T; Ruidavets JB; Kassner U; Duparc T; Combes G; Perret B; Genoux A; Schumann F; Bobbert T; Steinhagen-Thiessen E; Martinez LO
    Vascul Pharmacol; 2020 Dec; 135():106804. PubMed ID: 32987194
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low Density Lipoprotein (LDL) Cholesterol as a Causal Role for Atherosclerotic Disease: Potential Role of PCSK9 Inhibitors.
    Del Pinto R; Grassi D; Properzi G; Desideri G; Ferri C
    High Blood Press Cardiovasc Prev; 2019 Jun; 26(3):199-207. PubMed ID: 31236902
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhancing the value of PCSK9 monoclonal antibodies by identifying patients most likely to benefit. A consensus statement from the National Lipid Association.
    Robinson JG; Jayanna MB; Brown AS; Aspry K; Orringer C; Gill EA; Goldberg A; Jones LK; Maki K; Dixon DL; Saseen JJ; Soffer D
    J Clin Lipidol; 2019; 13(4):525-537. PubMed ID: 31281070
    [TBL] [Abstract][Full Text] [Related]  

  • 19. LDL-cholesterol reduction in chronic kidney disease: options beyond statins.
    Goonasekera MA; Mafham MM; Haynes RJ
    Curr Opin Nephrol Hypertens; 2020 Sep; 29(5):480-488. PubMed ID: 32701596
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease.
    Sabatine MS; Giugliano RP; Keech AC; Honarpour N; Wiviott SD; Murphy SA; Kuder JF; Wang H; Liu T; Wasserman SM; Sever PS; Pedersen TR;
    N Engl J Med; 2017 May; 376(18):1713-1722. PubMed ID: 28304224
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 67.